Central Retinal Venous Occlusion Epidemiology Forecast 2025-2034

Central retinal vein occlusion (CRVO), a common retinal vascular disorder, has two types, namely, ischemic and non-ischemic, with some patients presenting intermediate features. Over 90% of patients with ischemic CRVO experience final visual acuity of 20/200 or worse. Anterior segment neovascularisation occurs in more than 60% of cases, with related complications typically arising within weeks to two years after the onset of the condition.

Central Retinal Venous Occlusion Epidemiology Forecast Report Coverage

The “Central Retinal Venous Occlusion Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of central retinal venous occlusion. It projects the future incidence and prevalence rates of central retinal venous occlusion across various populations. The study covers age, gender, and type as major determinants of the central retinal venous occlusion-affected population. The report highlights patterns in the prevalence of central retinal venous occlusion over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of central retinal venous occlusion in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Central Retinal Venous Occlusion Disease Overview

Central retinal venous occlusion (CRVO) occurs when the main vein draining blood from the retina becomes blocked, usually due to a blood clot. This blockage leads to impaired blood flow, causing retinal swelling, hemorrhages, and vision problems. Risk factors include high blood pressure, diabetes, glaucoma, and clotting disorders. Symptoms often include sudden, painless vision loss or blurring in one eye. CRVO is classified as non-ischemic or ischemic, with the latter posing a higher risk of severe vision loss. Treatment includes managing underlying conditions, anti-VEGF injections, or laser therapy to reduce complications.

Central Retinal Venous Occlusion: Treatment Overview

Central retinal vein occlusion (CRVO) treatment aims to manage complications, improve vision, and prevent progression. Management includes anti-vascular endothelial growth factor (VEGF) injections, corticosteroids, and addressing risk factors like hypertension and diabetes to reduce recurrence or bilateral involvement. Corticosteroid implants may also be employed in specific cases. Addressing underlying risk factors, such as hypertension, diabetes, and glaucoma, is critical to reducing recurrence and preventing bilateral involvement. For non-ischemic CRVO, complete recovery occurs in only 10% of cases, while 50% experience 20/200 or worse vision, and 34% convert to ischemic CRVO within three years.

Epidemiology

The central retinal venous occlusion epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for central retinal venous occlusion by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for central retinal venous occlusion and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• CRVO is slightly more common in males and occurs in over 90% of individuals aged above 50 years, though cases are reported in all age groups. There is no racial preference.
• Non-ischemic CRVO resolves completely in approximately 10% of cases, while 50% of patients experience vision of 20/200 or worse. Around one-third of cases progress to ischemic CRVO, often within 6-12 months.
• Retinal vein occlusion may develop in the fellow eye in 7% of cases within two years. The 4-year risk is 2.5% in the same eye and 11.9% in the fellow eye.
• Hypertension, present in 73% of patients over 50 and 25% of younger patients, significantly increases the risk of recurrence in either eye.

Country-wise Central Retinal Venous Occlusion Epidemiology

The central retinal venous occlusion epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of central retinal vein occlusion (CRVO) varies globally, being the second most common retinal vascular disorder. Non-ischemic CRVO is more prevalent than the ischemic type. In the United States, Europe, Asia, and Australia, pooled data indicate CRVO affects 0.8 per 1,000 individuals. The Beaver Dam Eye Study reported a 15-year cumulative incidence of 0.5%. In Israel, the 4-year incidence is 2.14 per 1,000 individuals over 40 years, increasing to 5.36 per 1,000 above 64 years. In Australia, prevalence ranges from 0.7% at ages 49-60 to 4.6% in those over 80 years.

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of central retinal venous occlusion based on several factors.
• Central Retinal Venous Occlusion Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The report helps to identify the patient population and the unmet needs of central retinal venous occlusion are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of central retinal venous occlusion epidemiology in the 8 major markets?
• What will be the total number of patients with central retinal venous occlusion across the 8 major markets during the forecast period?
• What was the country-wise prevalence of central retinal venous occlusion in the 8 major markets in the historical period?
• Which country will have the highest number of central retinal venous occlusion patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of central retinal venous occlusion during the forecast period of 2025-2034?
• What are the currently available treatments for central retinal venous occlusion?
• What are the disease risks, signs, symptoms, and unmet needs of central retinal venous occlusion?

This product will be delivered within 3-5 business days.